ThinkCyte

Executive Summary

ThinkCyte is a Japanese biotechnology company pioneering AI-powered cell analysis and sorting through its proprietary Ghost Cytometry platform. This technology combines high-throughput morphological profiling with machine learning to enable label-free characterization and isolation of cells, eliminating the need for traditional fluorescent markers. Founded in 2020 and based in Tokyo, the company targets high-value applications in oncology, immunology, and regenerative medicine, including cellular therapy development, drug discovery, and disease diagnostics. By offering a faster, more objective, and scalable approach to cell analysis, ThinkCyte aims to address critical bottlenecks in precision medicine and bioprocessing. The platform's ability to analyze cells based on native physical and morphological features provides unique advantages for identifying rare cell populations and assessing cell quality in manufacturing settings. With a team of 50-200 employees, ThinkCyte is positioned as an emerging leader in the next generation of cytometry tools, seeking to displace conventional fluorescence-based methods in both research and clinical workflows.

Upcoming Catalysts (preview)

• Q4 2026Partnership with major pharmaceutical or CRO for cell therapy quality control65% success
• Q2 2027Launch of Ghost Cytometry system for clinical diagnostics use50% success
• Q3 2026Series B or later funding round to support global expansion70% success